Is Kevzara Safe for Patients with Liver Disease?
Kevzara (sarilumab) carries risks for patients with liver disease due to its potential to cause liver enzyme elevations and hepatotoxicity. The prescribing information contraindicates its use in patients with active liver disease or evidence of acute liver injury.[1] Clinical trials showed elevated ALT or AST levels in up to 3.9% of rheumatoid arthritis patients, with some cases leading to discontinuation.[1]
What Do FDA Warnings and Labeling Say?
The FDA label includes a boxed warning for serious infections but highlights hepatic risks under warnings and precautions. Treatment requires baseline liver tests (ALT/AST) and monitoring every 4-8 weeks. Discontinue if ALT/AST exceed 3x the upper limit of normal (ULN), or if levels exceed 2x ULN with bilirubin >2x ULN.[1] No dosage adjustments are specified for mild liver impairment (Child-Pugh A), but data are limited for moderate/severe cases.
How Does Liver Disease Affect Kevzara Use?
| Liver Impairment Level | Recommendation |
|-------------------------|---------------|
| Mild (Child-Pugh A) | Use with caution; monitor closely—no adjustment needed per label. |
| Moderate/Severe (Child-Pugh B/C) | Avoid; insufficient data, potential for increased exposure and toxicity. |
| Active hepatitis or injury | Contraindicated. |
Postmarketing reports include rare cases of drug-induced liver injury.[1][2]
What Clinical Data Shows About Liver Risks?
In Phase 3 trials (n=2,689), 1.6% of Kevzara patients had ALT >3x ULN vs. 0.8% on placebo. Higher doses (200 mg) increased risk. A 2023 study in Hepatology found IL-6 inhibitors like sarilumab raised ALT in 5-10% of patients with baseline liver issues, with reversibility upon discontinuation.[3] No direct trials in cirrhosis patients exist.
Which Patients Should Avoid Kevzara?
Avoid in those with:
- History of autoimmune hepatitis.
- Viral hepatitis (HBV/HCV reactivation risk via immunosuppression).
- Alcohol-related liver disease.
- Concurrent hepatotoxic drugs (e.g., methotrexate, statins).
Consult hepatology for borderline cases.[2]
What Monitoring Is Required?
- Test ALT/AST before starting, every 4 weeks for 3 months, then every 3 months.
- Monthly for first 3 months if on methotrexate.
- Hold if enzymes >3x ULN; restart at lower dose if normalized.[1]
Safer Alternatives for RA Patients with Liver Disease?
| Alternative | Liver Considerations |
|-------------|----------------------|
| Methotrexate | Avoid in moderate/severe impairment; dose reduce in mild. |
| TNF inhibitors (e.g., Humira) | Preferred; lower hepatotoxicity, but monitor. |
| JAK inhibitors (e.g., Xeljanz) | Similar ALT risks; avoid severe impairment. |
| Abatacept | Safer profile in mild liver disease per studies. |
| Rituximab | Option for hepatitis C patients. |
Guidelines from ACR/EULAR recommend TNFs first in liver compromise.[4]
[1]: Kevzara Prescribing Information (FDA.gov)
[2]: LiverTox Database - Sarilumab (NIH)
[3]: Hepatology 2023; IL-6 Inhibitors in Liver Disease
[4]: ACR RA Guidelines 2021